Drawing for BRISTOL MYERS SQUIBB

USPTO serial 88703275

BRISTOL MYERS SQUIBB

Reviewed by CopyMark Law Group

Reg. 6702019Status 700Registered
Filing date
Status date
Registration date
Apr 12, 2022
Examiner
MORRIS, ALINA S.
Law office
PUBLICATION AND ISSUE SECTION

What this means

Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.

Status 700: Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six.

Need help with BRISTOL MYERS SQUIBB?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Marilyn F. Kelly

Marilyn F. Kelly Bristol-Myers Squibb CompanyP.O. Box 4000Trademark Dept., Mailstop D4243Princeton, NJ 08648-4000

Goods and services

ClassDescriptionStatusFirst use
005Pharmaceutical preparations for human use for the treatment and prevention of cardiovascular diseases, central nervous system diseases and disorders, stroke, cancer, inflammation and inflammatory diseases, respiratory and infectious diseases, auto-immune diseases, solid organ transplant rejection, myeloproliferative diseases, myelofibrosis, leukemia, lymphoma, multiple myeloma, autoinflammatory disease, blood disease, tumors, multiple sclerosis, arthritis; Pharmaceutical preparations for human use, namely, antibiotics, immunosuppressants, immunotherapies for the treatment of cancer; Pharmaceutical preparations for human use that modulate the immune system; Pharmaceutical and biological preparations for human use for immunotherapy, including T Cell therapyACTIVEMar 4, 2020
042Pharmaceutical research and development servicesACTIVEMar 4, 2020

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Aug 2, 2023TCCATEAS CHANGE OF CORRESPONDENCE RECEIVED—
Aug 2, 2023ARAAATTORNEY/DOM.REP.REVOKED AND/OR APPOINTEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Aug 2, 2023REAPTEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED—
Aug 2, 2023CHANAPPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED—
Aug 2, 2023COARTEAS CHANGE OF OWNER ADDRESS RECEIVED—
Apr 12, 2022R.PRREGISTERED-PRINCIPAL REGISTERYour trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive.
Mar 5, 2022SUNANOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED—
Mar 4, 2022CNPRALLOWED PRINCIPAL REGISTER - SOU ACCEPTED—
Feb 19, 2022EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED—
Feb 18, 2022SUPCSTATEMENT OF USE PROCESSING COMPLETE—
Feb 18, 2022EX2GSOU EXTENSION 2 GRANTED—
Feb 15, 2022TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Feb 9, 2022INCEITU OFFICE ACTION ISSUED FOR EXTENSION REQUEST—
Feb 9, 2022AITUCASE ASSIGNED TO INTENT TO USE PARALEGAL—
Feb 2, 2022IUAFUSE AMENDMENT FILED—
Feb 2, 2022EXT2SOU EXTENSION 2 FILED—
Feb 2, 2022EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Feb 2, 2022EISUTEAS STATEMENT OF USE RECEIVEDThe applicant filed a Statement of Use with specimens showing the mark in actual commerce. The USPTO will review the filing for compliance. If accepted, the mark can proceed to registration; if deficient, the USPTO may issue a requirement or office action.
Aug 4, 2021EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED—
Aug 2, 2021EX1GSOU EXTENSION 1 GRANTED—
Aug 2, 2021EXT1SOU EXTENSION 1 FILED—
Aug 2, 2021EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Feb 2, 2021NOAMNOA E-MAILED - SOU REQUIRED FROM APPLICANTA Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date.
Dec 8, 2020NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
Dec 8, 2020PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Nov 18, 2020NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
Oct 29, 2020CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Oct 29, 2020TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Oct 29, 2020CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Oct 29, 2020ERFRTEAS REQUEST FOR RECONSIDERATION RECEIVED—
May 5, 2020GNFNNOTIFICATION OF FINAL REFUSAL EMAILED—
May 5, 2020GNFRFINAL REFUSAL E-MAILEDA final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon.
May 5, 2020CNFRFINAL REFUSAL WRITTENA final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon.
Apr 21, 2020TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Apr 21, 2020CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Apr 21, 2020TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Feb 12, 2020GNRNNOTIFICATION OF NON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Feb 12, 2020GNRTNON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Feb 12, 2020CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Feb 11, 2020DOCKASSIGNED TO EXAMINER—
Dec 3, 2019MDSCNOTICE OF DESIGN SEARCH CODE E-MAILED—
Dec 1, 2019NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Nov 26, 2019NWAPNEW APPLICATION ENTERED—

Frequently asked questions

Related guidance